5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Expected value of artificial intelligence in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

      1 , 2 , 3 , 4 , 5 , 6 , 2 , 7 , 8 , 9 , 10 , 11 , 12 , 7 , 13 , 12 , 14 , 1 , 15 , 16 , 17 , 8 , 9 , 18 , 19 , 20 , 21 , 22 , 23 , 19 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 13 , 34 , 26 , 27 , 35 , 36 , 37 , 26 , 27 , 5
      Endoscopy
      Georg Thieme Verlag KG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This ESGE Position Statement defines the expected value of artificial intelligence (AI) for the diagnosis and management of gastrointestinal neoplasia within the framework of the performance measures already defined by ESGE. This is based on the clinical relevance of the expected task and the preliminary evidence regarding artificial intelligence in artificial or clinical settings.

          Main recommendations: (1) For acceptance of AI in assessment of completeness of upper GI endoscopy, the adequate level of mucosal inspection with AI should be comparable to that assessed by experienced endoscopists. (2) For acceptance of AI in assessment of completeness of upper GI endoscopy, automated recognition and photodocumentation of relevant anatomical landmarks should be obtained in ≥90% of the procedures. (3) For acceptance of AI in the detection of Barrett’s high grade intraepithelial neoplasia or cancer, the AI-assisted detection rate for suspicious lesions for targeted biopsies should be comparable to that of experienced endoscopists with or without advanced imaging techniques. (4) For acceptance of AI in the management of Barrett’s neoplasia, AI-assisted selection of lesions amenable to endoscopic resection should be comparable to that of experienced endoscopists. (5) For acceptance of AI in the diagnosis of gastric precancerous conditions, AI-assisted diagnosis of atrophy and intestinal metaplasia should be comparable to that provided by the established biopsy protocol, including the estimation of extent, and consequent allocation to the correct endoscopic surveillance interval. (6) For acceptance of artificial intelligence for automated lesion detection in small-bowel capsule endoscopy (SBCE), the performance of AI-assisted reading should be comparable to that of experienced endoscopists for lesion detection, without increasing but possibly reducing the reading time of the operator. (7) For acceptance of AI in the detection of colorectal polyps, the AI-assisted adenoma detection rate should be comparable to that of experienced endoscopists. (8) For acceptance of AI optical diagnosis (computer-aided diagnosis [CADx]) of diminutive polyps (≤5 mm), AI-assisted characterization should match performance standards for implementing resect-and-discard and diagnose-and-leave strategies. (9) For acceptance of AI in the management of polyps ≥ 6 mm, AI-assisted characterization should be comparable to that of experienced endoscopists in selecting lesions amenable to endoscopic resection.

          Related collections

          Most cited references117

          • Record: found
          • Abstract: not found
          • Article: not found

          Distinctive Image Features from Scale-Invariant Keypoints

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Quality indicators for colonoscopy and the risk of interval cancer.

            Although rates of detection of adenomatous lesions (tumors or polyps) and cecal intubation are recommended for use as quality indicators for screening colonoscopy, these measurements have not been validated, and their importance remains uncertain. We used a multivariate Cox proportional-hazards regression model to evaluate the influence of quality indicators for colonoscopy on the risk of interval cancer. Data were collected from 186 endoscopists who were involved in a colonoscopy-based colorectal-cancer screening program involving 45,026 subjects. Interval cancer was defined as colorectal adenocarcinoma that was diagnosed between the time of screening colonoscopy and the scheduled time of surveillance colonoscopy. We derived data on quality indicators for colonoscopy from the screening program's database and data on interval cancers from cancer registries. The primary aim of the study was to assess the association between quality indicators for colonoscopy and the risk of interval cancer. A total of 42 interval colorectal cancers were identified during a period of 188,788 person-years. The endoscopist's rate of detection of adenomas was significantly associated with the risk of interval colorectal cancer (P=0.008), whereas the rate of cecal intubation was not significantly associated with this risk (P=0.50). The hazard ratios for adenoma detection rates of less than 11.0%, 11.0 to 14.9%, and 15.0 to 19.9%, as compared with a rate of 20.0% or higher, were 10.94 (95% confidence interval [CI], 1.37 to 87.01), 10.75 (95% CI, 1.36 to 85.06), and 12.50 (95% CI, 1.51 to 103.43), respectively (P=0.02 for all comparisons). The adenoma detection rate is an independent predictor of the risk of interval colorectal cancer after screening colonoscopy. 2010 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adenoma Detection Rate and Risk of Colorectal Cancer and Death

              New England Journal of Medicine, 370(14), 1298-1306
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Endoscopy
                Endoscopy
                Georg Thieme Verlag KG
                0013-726X
                1438-8812
                November 29 2022
                December 2022
                October 21 2022
                December 2022
                : 54
                : 12
                : 1211-1231
                Affiliations
                [1 ]III Medizinische Klinik, Universitatsklinikum Augsburg, Augsburg, Germany
                [2 ]Department of Gastroenterology and Hepatology, Catholic University of Leuven (KUL), TARGID, University Hospital Leuven, Leuven, Belgium
                [3 ]Gastroenterology and Digestive Endoscopy Unit, Ospedale dei Castelli Hospital, Ariccia, Rome, Italy
                [4 ]Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Italy
                [5 ]Department of Gastroenterology, Porto Comprehensive Cancer Center, and RISE@CI-IPOP (Health Research Network), Porto, Portugal
                [6 ]MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal
                [7 ]Endoscopy Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
                [8 ]Wellcome/EPSRC Centre for Interventional and Surgical Sciences, University College London Hospital, London, UK
                [9 ]Division of Surgery and Interventional Sciences, University College London Hospital, London, UK
                [10 ]Gastrointestinal Services, University College London Hospital, London, UK
                [11 ]Gastroenterology Department, Portuguese Oncology Institute of Coimbra, Coimbra, Portugal
                [12 ]Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands
                [13 ]Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
                [14 ]Department of Medicine I, Josephs-Hospital Warendorf, Academic Teaching Hospital, University of Muenster, Warendorf, Germany
                [15 ]Department of Electrical Engineering (ESAT/PSI), Medical Imaging Research Center, KU Leuven, Leuven, Belgium
                [16 ]Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel
                [17 ]2nd Medical Department, Barmherzige Schwestern Krankenhaus, Vienna, Austria
                [18 ]Servicio de Gastroenterología, Hospital General Universitario Dr. Balmis, Instituto de Investigación Biomédica de Alicante ISABIAL, Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
                [19 ]Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway
                [20 ]Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland
                [21 ]Department of Oncological Gastroenterology and Department of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
                [22 ]Endoscopy Department, Yaroslavl Regional Cancer Hospital, Yaroslavl, Russian Federation
                [23 ]Department of Gastroenterology, Faculty of Additional Professional Education, N.A. Pirogov Russian National Research Medical University, Moscow, Russian Federation
                [24 ]Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
                [25 ]European Hospital, Marseille, France
                [26 ]Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy
                [27 ]IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
                [28 ]Gastroenterology Unit, Valduce Hospital, Como, Italy
                [29 ]North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, UK
                [30 ]Population Health Sciences Institute, Newcastle University, Newcastle, UK
                [31 ]Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
                [32 ]Gastroenterology and Hepatology Division, University of Kansas School of Medicine, Kansas, USA
                [33 ]Kansas City VA Medical Center, Kansas City, USA
                [34 ]Digestive Endoscopy, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy
                [35 ]Department of Gastroenterology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK
                [36 ]Ellen and Pinchas Mamber Institute of Gastroenterology and Hepatology, Emek Medical Center, Afula, Israel
                [37 ]Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
                Article
                10.1055/a-1950-5694
                36270318
                ae573e72-14c2-4e5b-98f9-0ad52de38be8
                © 2022
                History

                Comments

                Comment on this article